US5362866A
(en)
*
|
1983-09-02 |
1994-11-08 |
Molecular Biosystems, Inc. |
Oligonucleotide polymeric support system with an oxidation cleavable link
|
US4959463A
(en)
*
|
1985-10-15 |
1990-09-25 |
Genentech, Inc. |
Intermediates
|
US5204456A
(en)
*
|
1986-04-08 |
1993-04-20 |
Commissariat A L'energie Atomique |
Derivatives of nucleosides and their use for the synthesis of oligonucleotides
|
FR2596761B1
(fr)
*
|
1986-04-08 |
1988-05-20 |
Commissariat Energie Atomique |
Derives de nucleosides et leur utilisation pour la synthese d'oligonucleotides
|
US4816571A
(en)
*
|
1987-06-04 |
1989-03-28 |
Applied Biosystems, Inc. |
Chemical capping by phosphitylation during oligonucleotide synthesis
|
US6756496B1
(en)
|
1988-09-23 |
2004-06-29 |
Isis Pharmaceuticals, Inc. |
Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues
|
US5194599A
(en)
*
|
1988-09-23 |
1993-03-16 |
Gilead Sciences, Inc. |
Hydrogen phosphonodithioate compositions
|
US5262530A
(en)
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
GB8902689D0
(en)
*
|
1989-02-07 |
1989-03-30 |
Ici Plc |
Assay method
|
US5149798A
(en)
*
|
1989-04-06 |
1992-09-22 |
Worcester Foundation For Experimental Biology |
Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
|
US5256775A
(en)
*
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
US6300486B1
(en)
*
|
1989-06-15 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Large scale synthesis of oligonucleotides and their associated analogs
|
US5204455A
(en)
*
|
1989-06-15 |
1993-04-20 |
Froehler Brian C |
Monomethoxytrityl protected oligonucleotides bound to a solid support
|
US5164491A
(en)
*
|
1989-06-15 |
1992-11-17 |
Gilead Sciences |
Large scale synthesis of oligonucleotides and their associated analogs
|
WO1991006678A1
(en)
*
|
1989-10-26 |
1991-05-16 |
Sri International |
Dna sequencing
|
US7037646B1
(en)
|
1990-01-11 |
2006-05-02 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
US5321131A
(en)
*
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
US5166195A
(en)
*
|
1990-05-11 |
1992-11-24 |
Isis Pharmaceuticals, Inc. |
Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
|
US5214134A
(en)
*
|
1990-09-12 |
1993-05-25 |
Sterling Winthrop Inc. |
Process of linking nucleosides with a siloxane bridge
|
US5432272A
(en)
*
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
US5594121A
(en)
*
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
US5610274A
(en)
*
|
1991-11-20 |
1997-03-11 |
Cpg, Inc. |
Production and use of magnetic porous inorganic materials
|
US5734020A
(en)
*
|
1991-11-20 |
1998-03-31 |
Cpg, Inc. |
Production and use of magnetic porous inorganic materials
|
TW393513B
(en)
*
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
EP1256589A3
(de)
*
|
1991-11-26 |
2003-09-17 |
Isis Pharmaceuticals, Inc. |
Oligomere, die modifizierte PyrimIdine enthalten
|
US6235887B1
(en)
|
1991-11-26 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
|
WO1993012135A1
(en)
|
1991-12-12 |
1993-06-24 |
Gilead Sciences, Inc. |
Nuclease stable and binding competent oligomers and methods for their use
|
US5817781A
(en)
*
|
1992-06-01 |
1998-10-06 |
Gilead Sciences, Inc. |
Modified internucleoside linkages (II)
|
US5583211A
(en)
*
|
1992-10-29 |
1996-12-10 |
Beckman Instruments, Inc. |
Surface activated organic polymers useful for location - specific attachment of nucleic acids, peptides, proteins and oligosaccharides
|
NZ261480A
(en)
*
|
1993-01-08 |
1997-05-26 |
Hybridon Inc |
Preparation of dimeric nucleotide derivatives containing phosphonothionate internucleotide linkages
|
US6087491A
(en)
*
|
1993-01-08 |
2000-07-11 |
Hybridon, Inc. |
Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
|
US5476925A
(en)
*
|
1993-02-01 |
1995-12-19 |
Northwestern University |
Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
|
HUT74597A
(en)
*
|
1993-06-23 |
1997-01-28 |
Genesys Pharma Inc |
Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
|
US6653458B1
(en)
|
1993-09-03 |
2003-11-25 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides
|
FR2714061B1
(fr)
*
|
1993-12-16 |
1996-03-08 |
Genset Sa |
Procédé de préparation de polynucléotides sur support solide et appareil permettant sa mise en Óoeuvre.
|
US5637684A
(en)
*
|
1994-02-23 |
1997-06-10 |
Isis Pharmaceuticals, Inc. |
Phosphoramidate and phosphorothioamidate oligomeric compounds
|
US5623068A
(en)
*
|
1994-03-07 |
1997-04-22 |
Beckman Instruments, Inc. |
Synthesis of DNA using substituted phenylacetyl-protected nucleotides
|
US6639061B1
(en)
|
1999-07-07 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
C3′-methylene hydrogen phosphonate oligomers and related compounds
|
US5514789A
(en)
*
|
1994-04-21 |
1996-05-07 |
Barrskogen, Inc. |
Recovery of oligonucleotides by gas phase cleavage
|
US5990300A
(en)
*
|
1994-09-02 |
1999-11-23 |
Andrew C. Hiatt |
Enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
|
US5872244A
(en)
*
|
1994-09-02 |
1999-02-16 |
Andrew C. Hiatt |
3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
|
US6232465B1
(en)
|
1994-09-02 |
2001-05-15 |
Andrew C. Hiatt |
Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
|
US6214987B1
(en)
|
1994-09-02 |
2001-04-10 |
Andrew C. Hiatt |
Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides
|
US5763594A
(en)
*
|
1994-09-02 |
1998-06-09 |
Andrew C. Hiatt |
3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
|
US5808045A
(en)
*
|
1994-09-02 |
1998-09-15 |
Andrew C. Hiatt |
Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
|
US5639875A
(en)
*
|
1995-02-01 |
1997-06-17 |
Hybridon, Inc. |
Methods for H-phosphonate syntheis of oligonucleotides using triphosgene
|
US5683875A
(en)
*
|
1995-05-04 |
1997-11-04 |
Hewlett-Packard Company |
Method for detecting a target nucleic acid analyte in a sample
|
AU5958196A
(en)
*
|
1995-06-01 |
1996-12-24 |
Hybridon, Inc. |
Novel base protecting groups for oligonucleotide synthesis
|
US6140482A
(en)
*
|
1995-06-01 |
2000-10-31 |
Hybridon, Inc. |
Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same
|
US5955599A
(en)
*
|
1995-06-01 |
1999-09-21 |
Hybridon, Inc. |
Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages
|
US6531589B1
(en)
|
1995-06-01 |
2003-03-11 |
Hybridon, Inc. |
Base protecting groups and synthons for oligonucleotide synthesis
|
US5962674A
(en)
*
|
1995-06-01 |
1999-10-05 |
Hybridon, Inc. |
Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
|
US5856464A
(en)
*
|
1995-06-07 |
1999-01-05 |
Lajolla Pharmaceutical Company |
Selective capping solution phase oligonucleotide synthesis
|
JP2000500740A
(ja)
|
1995-10-19 |
2000-01-25 |
プロリゴ・エルエルシー |
オリゴヌクレオチドの溶液相合成方法
|
WO1998017675A1
(en)
*
|
1996-10-18 |
1998-04-30 |
Hybridon, Inc. |
Improved methods for h-phosphonate synthesis of mono- and oligonucleotides
|
US5705629A
(en)
*
|
1995-10-20 |
1998-01-06 |
Hybridon, Inc. |
Methods for H-phosphonate synthesis of mono- and oligonucleotides
|
US5902881A
(en)
*
|
1997-03-03 |
1999-05-11 |
Isis Pharmaceuticals, Inc. |
Reagent useful for synthesizing sulfurized oligonucleotide analogs
|
US5760209A
(en)
*
|
1997-03-03 |
1998-06-02 |
Isis Pharmaceuticals, Inc. |
Protecting group for synthesizing oligonucleotide analogs
|
ES2131463B1
(es)
|
1997-04-08 |
2000-03-01 |
Lilly Sa |
Derivados de ciclopropilglicina con propiedades farmaceuticas.
|
US6114519A
(en)
*
|
1997-10-15 |
2000-09-05 |
Isis Pharmaceuticals, Inc. |
Synthesis of sulfurized oligonucleotides
|
US6242591B1
(en)
*
|
1997-10-15 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Synthesis of sulfurized 2'-substituted oligonucleotides
|
US6441150B1
(en)
*
|
1997-12-16 |
2002-08-27 |
Isis Pharmaceuticals, Inc. |
Compounds for the Synthesis of Nucleotide or oligonucleotide phosphoramidites
|
US7273933B1
(en)
*
|
1998-02-26 |
2007-09-25 |
Isis Pharmaceuticals, Inc. |
Methods for synthesis of oligonucleotides
|
US6207819B1
(en)
*
|
1999-02-12 |
2001-03-27 |
Isis Pharmaceuticals, Inc. |
Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
|
CA2370478A1
(en)
|
1999-03-24 |
2000-09-28 |
Serge L. Beaucage |
N-acylphosphoramidites and their use in oligonucleotide synthesis
|
US7435390B2
(en)
*
|
2001-01-26 |
2008-10-14 |
Third Wave Technologies, Inc. |
Nucleic acid synthesizers
|
US20030072689A1
(en)
*
|
2001-08-15 |
2003-04-17 |
Third Wave Technologies, Inc. |
Polymer synthesizer
|
US6932943B1
(en)
|
2001-01-26 |
2005-08-23 |
Third Wave Technologies |
Nucleic acid synthesizers
|
US20080261220A1
(en)
*
|
2000-11-30 |
2008-10-23 |
Third Wave Technologies, Inc. |
Nucleic Acid Detection Assays
|
EP1343802B1
(de)
*
|
2000-12-05 |
2012-05-30 |
Avecia Biotechnology Inc |
Verfahren zur herstellung von oligonukleotiden
|
WO2002081476A1
(en)
*
|
2001-04-06 |
2002-10-17 |
Micrologix Biotech, Inc. |
Thiophosphate nucleic acid-based compounds
|
US7355037B2
(en)
|
2001-12-03 |
2008-04-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Thermolabile hydroxyl protecting groups and methods of use
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
WO2003064621A2
(en)
|
2002-02-01 |
2003-08-07 |
Ambion, Inc. |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
EP3415625A1
(de)
|
2002-02-01 |
2018-12-19 |
Life Technologies Corporation |
Doppelsträngige oligonukleotide
|
US20050009051A1
(en)
*
|
2002-09-27 |
2005-01-13 |
Board Of Regents, The University Of Texas |
Diagnosis of mould infection
|
AU2004212953B2
(en)
|
2003-02-14 |
2010-03-11 |
The Curators Of The University Of Missouri |
Contraceptive methods and compositions related to proteasomal interference
|
CN1950519A
(zh)
*
|
2004-02-27 |
2007-04-18 |
哈佛大学的校长及成员们 |
聚合酶群落荧光原位测序珠子
|
AU2005250432B2
(en)
|
2004-05-28 |
2011-09-15 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
US7678824B2
(en)
|
2004-09-14 |
2010-03-16 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods for treatment with bucindolol based on genetic targeting
|
ES2534304T3
(es)
|
2004-11-12 |
2015-04-21 |
Asuragen, Inc. |
Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
|
WO2006065751A2
(en)
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
WO2006110314A2
(en)
|
2005-03-25 |
2006-10-19 |
Ambion, Inc. |
Methods and compositions for depleting abundant rna transcripts
|
JP5520605B2
(ja)
|
2006-09-19 |
2014-06-11 |
アシュラジェン インコーポレイテッド |
膵臓疾患で差次的に発現されるマイクロrnaおよびその使用
|
DK2104737T3
(da)
|
2006-12-08 |
2013-05-27 |
Asuragen Inc |
Funktioner og formål for let-7 mikro-RNAer
|
JP5677703B2
(ja)
|
2008-01-10 |
2015-02-25 |
リサーチ ディベロップメント ファウンデーション |
Ehrlichiachaffeensisにのためのワクチンおよび診断
|
DK2245464T3
(en)
|
2008-01-25 |
2017-02-20 |
Multivir Inc |
P53 BIOMARKETS
|
EP2285960B1
(de)
|
2008-05-08 |
2015-07-08 |
Asuragen, INC. |
Zusammensetzungen und verfahren in zusammenhang mit der mirna-184modulation von neovaskularisation oder angiogenese
|
US20100047876A1
(en)
*
|
2008-08-08 |
2010-02-25 |
President And Fellows Of Harvard College |
Hierarchical assembly of polynucleotides
|
CN102272157B
(zh)
|
2008-11-07 |
2015-11-25 |
研究发展基金会 |
用于抑制cripto/grp78复合物形成和信号的组合物和方法
|
WO2010068738A1
(en)
|
2008-12-10 |
2010-06-17 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
EP2379720B1
(de)
|
2009-01-20 |
2016-08-17 |
Alona Zilberberg |
Durch den promoter mir-21 angetriebene gezielte krebstherapie
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
EP2449104B1
(de)
|
2009-06-29 |
2014-06-04 |
Luminex Corporation |
Chimäre primer mit haarnadel-konformationen und verwendungsverfahren dafür
|
CA2771769C
(en)
|
2009-08-28 |
2019-10-29 |
Research Development Foundation |
Urocortin 2 analogs and uses thereof
|
WO2011032088A1
(en)
|
2009-09-11 |
2011-03-17 |
Arca Biopharma, Inc. |
Polymorphisms in the pde3a gene
|
ES2587191T3
(es)
|
2009-12-23 |
2016-10-21 |
Arca Biopharma, Inc. |
Métodos y composiciones para enfermedades y afecciones cardiovasculares
|
WO2011099664A1
(ko)
|
2010-02-12 |
2011-08-18 |
엠앤디(주) |
Hpv 유전자형 진단용 프로브 및 그 분석방법
|
EP3028699B1
(de)
|
2010-02-25 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Braf-mutationen für resistenz gegen braf-inhibitoren
|
ES2631458T3
(es)
|
2010-03-04 |
2017-08-31 |
Interna Technologies B.V. |
Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
|
US20130131148A1
(en)
|
2010-04-12 |
2013-05-23 |
Noam Shomron |
Micro-rna for cancer diagnosis, prognosis and therapy
|
WO2011156588A1
(en)
|
2010-06-09 |
2011-12-15 |
Dana-Farber Cancer Institute, Inc. |
A mek 1 mutation conferring resistance to raf and mek inhibitors
|
EP2591106A1
(de)
|
2010-07-06 |
2013-05-15 |
InteRNA Technologies B.V. |
Mirna und ihre diagnostischen und therapeutischen verwendungen für mit melanomen assoziierte erkrankungen oder leiden oder für mit dem aktivierten braf-pfad assoziierte erkrankungen oder leiden
|
CA2814049C
(en)
|
2010-10-08 |
2021-07-13 |
President And Fellows Of Harvard College |
High-throughput single cell barcoding
|
EP2772550B1
(de)
|
2010-11-17 |
2017-03-29 |
Interpace Diagnostics, LLC |
MiRNA als Biomarker zur Unterscheidung zwischen benignen und malignen Thyroid-Neoplasien
|
EP2474617A1
(de)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
MIR zur Behandlung von Neoangiogenese
|
CN103459598B
(zh)
|
2011-02-03 |
2016-08-10 |
米尔纳医疗股份有限公司 |
Mir-124的合成模拟物
|
SG192252A1
(en)
|
2011-02-03 |
2013-09-30 |
Mirna Therapeutics Inc |
Synthetic mimics of mir-34
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
EP2755663A4
(de)
|
2011-09-13 |
2015-10-07 |
Ottawa Hospital Res Inst |
Microrna-inhibitoren
|
EP2766498B1
(de)
|
2011-10-14 |
2019-06-19 |
President and Fellows of Harvard College |
Sequenzierung durch strukturanordnung
|
US20130157884A1
(en)
|
2011-10-26 |
2013-06-20 |
Asuragen, Inc. |
Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
|
ES2688619T3
(es)
|
2011-12-22 |
2018-11-05 |
Interna Technologies B.V. |
MiARN para tratar el cáncer de cabeza y de cuello
|
US9914967B2
(en)
|
2012-06-05 |
2018-03-13 |
President And Fellows Of Harvard College |
Spatial sequencing of nucleic acids using DNA origami probes
|
CN108875312A
(zh)
|
2012-07-19 |
2018-11-23 |
哈佛大学校长及研究员协会 |
利用核酸存储信息的方法
|
WO2014045126A2
(en)
|
2012-09-18 |
2014-03-27 |
Uti Limited Partnership |
Treatment of pain by inhibition of usp5 de-ubiquitinase
|
US20140100124A1
(en)
|
2012-10-04 |
2014-04-10 |
Asuragen, Inc. |
Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
|
US9476089B2
(en)
|
2012-10-18 |
2016-10-25 |
President And Fellows Of Harvard College |
Methods of making oligonucleotide probes
|
EP3800256A1
(de)
|
2012-11-06 |
2021-04-07 |
InteRNA Technologies B.V. |
Kombination zur therapeutischen verwendung bei krankheiten oder zuständen im zusammenhang mit melanomen oder bei krankheiten oder zuständen im zusammenhang mit dem aktivierten b-raf-signalweg
|
WO2014116721A1
(en)
|
2013-01-22 |
2014-07-31 |
The Arizona Board Of Regents For And On Behalf Of Arizona State University |
Geminiviral vector for expression of rituximab
|
CN105143470B
(zh)
|
2013-02-28 |
2020-06-09 |
德克萨斯大学系统董事会 |
用于将癌症分类为易感于tmepai定向疗法以及治疗所述癌症的方法
|
EP2971184B1
(de)
|
2013-03-12 |
2019-04-17 |
President and Fellows of Harvard College |
Verfahren zur erzeugung einer dreidimensionalen nukleinsäure mit matrix
|
EP3404116B1
(de)
|
2013-03-15 |
2022-10-19 |
The University of Chicago |
Verfahren und zusammensetzungen in zusammenhang mit t-zell aktivität
|
WO2015070050A1
(en)
|
2013-11-08 |
2015-05-14 |
Baylor Research Institute |
Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure
|
US11421229B2
(en)
|
2015-02-20 |
2022-08-23 |
Baylor College Of Medicine |
p63 inactivation for the treatment of heart failure
|
EP3436049B1
(de)
|
2016-03-31 |
2022-01-12 |
Baylor Research Institute |
Angiopoietin-ähnliches protein 8 (angptl8)
|
WO2018053232A1
(en)
|
2016-09-16 |
2018-03-22 |
Bio-Path Holdings, Inc. |
Combination therapy with liposomal antisense oligonucleotides
|
WO2019086603A1
(en)
|
2017-11-03 |
2019-05-09 |
Interna Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
WO2019227056A2
(en)
|
2018-05-25 |
2019-11-28 |
Arca Biopharma Inc. |
Methods and compositions involving bucindolol for the treatment of atrial fibrillation
|
AU2021374966A1
(en)
|
2020-11-09 |
2023-06-15 |
1E Therapeutics, Ltd. |
Catalytic sequence based methods of treating or preventing bacterial infections
|
IL304068A
(en)
|
2020-12-28 |
2023-08-01 |
1E Therapeutics Ltd |
DNA enzymes against p21 messenger RNA
|
WO2022144882A2
(en)
|
2020-12-28 |
2022-07-07 |
1E Therapeutics, Ltd. |
P21 mrna target areas for silencing
|
EP4320445A1
(de)
|
2021-04-08 |
2024-02-14 |
Joslin Diabetes Center, Inc. |
Verfahren zur diagnose und vorhersage von nierenabbau
|
WO2024015766A1
(en)
|
2022-07-12 |
2024-01-18 |
Topogene Inc. |
Scalable, submicron-resolution replication of dna arrays
|